<DOC>
	<DOCNO>NCT01583777</DOCNO>
	<brief_summary>The purpose trial study mass balance , pharmacokinetics ( PK ) , safety belinostat follow IV administration patient recurrent progressive malignancy .</brief_summary>
	<brief_title>Phase I Mass Balance , PK Safety Study 14C-Labeled Belinostat Patients With Advanced Cancer</brief_title>
	<detailed_description>This Phase 1 , open-label , single-dose study 14C-labeled belinostat determine rout elimination belinostat . A single dose 14C-labeled belinostat ( approximately 94.3 105 µCi , 1500 mg ) administer 30-minute IV infusion patient . Routes elimination belinostat metabolite assess estimate recovery total radioactivity parent belinostat period 7 day . Plasma sample take 3 day specify interval PK assessment . Total radioactivity plasma , urine , feces determine liquid scintillation counting . Concentrations belinostat plasma urine determine use validate liquid chromatography - tandem mass spectroscopy ( LC-MS/MS ) method . Selected plasma , urine , feces sample retain use metabolism investigation . Samples initially analyze use radio-high performance liquid chromatography ( HPLC ) determine number relative proportion belinostat metabolites present . Selected sample subsequently analyze use LC-MS identify major metabolite ( &gt; 10 % parent area curve [ AUC ] ) . If interest patient , treatment non-radiolabeled belinostat may continue 21-day cycle disease progression , initiation new anticancer therapy , adverse event ( AE ) may affect patient participation .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<criteria>1 . Signed informed consent document indicate understand purpose procedure require study willingness participate study . 2 . Histological confirmation cancer refractory intolerant standard therapy cancer standard therapy exist . 3 . Age study entry 18 year old . 4 . Availability stay research unit first 7 day . 5 . Adequate renal function define calculated creatinine clearance ( CrCl ) &gt; 45 mL/minute . 6 . Adequate hepatic function : total bilirubin &lt; 1.5 x upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 x ULN . 7 . Adequate hematopoietic function define absolute neutrophil count ( ANC ) &gt; 1000 cells/µL platelet count &gt; 50,000/µL . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 9 . Life expectancy least 12 week . 10 . If female , patient must postmenopausal least 1 year , document surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential practice birth control . Acceptable contraceptive method study intrauterine device ; diaphragm condom combination spermicidal foam jelly ; injectable , implantable , transdermal patch ; oral contraception . 11 . Female patient must negative pregnancy test Screening Visit end study treatment ( 30 day last dose belinostat ) . 1 . Known anal urinary incontinence . 2 . Diagnosis acute myelogenous leukemia ( AML ) , multiple myeloma , primary hepatic renal carcinoma . 3 . Inability consume oral fluid . 4 . Treatment drug know inhibit metabolic pathway ( glucuronidation , CYP system ) 4 week Screening Visit . 5 . Concurrent treatment diuretic laxatives . 6 . Radiotherapy involve mouth , esophagus , gastrointestinal tract 4 week Screening Visit . 7 . Polymorphism UGT1A1 . 8 . Known diagnosis human immunodeficiency virus ( HIV ) , hepatitis B C. 9 . Previous participation study utilize 14C . 10 . Body surface area &lt; 1.5 m2 . 11 . Ongoing medical history physical psychiatric illness , significant comorbidity , medical disorder cancer may require treatment make subject unlikely fully complete study . 12 . Use another investigational product anticancer agent within 4 week prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Belinostat</keyword>
</DOC>